Risk factors for fatty liver in the multicenter AIDS cohort study

American Journal of Gastroenterology

Volumn 109, Issue 5, 2014, Pages 695-704

  Price, Jennifer C ^a   Seaberg, Eric C ^b   Latanich, Rachel ^c   Budoff, Matthew J ^d   Kingsley, Lawrence A ^e   Palella, Frank J ^f   Witt, Mallory D ^g   Post, Wendy S ^b,c   Thio, Chloe L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; FATTY LIVER; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 GENE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ANTI-HIV AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INSULIN RESISTANCE; LIPASE; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, ABDOMINAL; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899994190     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.32     Document Type: Article

References (45)

1. Smith C. Factors associated with specific causes of death amongst HIVpositive individuals in the D:A:D Study. AIDS 2011; 24: 1537-48.
2. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-7.
3. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
4. Crum-Cianflone N, Dilay A, Collins G et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-73.
5. Guaraldi G, Squillace N, Stentarelli C et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-7.
6. Hadigan C, Liebau J, Andersen R et al. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46: 312-7.
7. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-50.
8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
9. Thomas EL, Hamilton G, Patel N et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-7.
10. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
11. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a metaanalysis of the risk factors. Hepatology 2010; 52: 71-8.
12. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
13. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
14. Trepo E, Pradat P, Potthoff A et al. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-9.
15. Valenti L, Rumi M, Galmozzi E et al. Patatin-like phospholipase domaincontaining 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53: 791-9.
16. Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
17. Lemoine M, Barbu V, Girard PM et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20: 387-95.
18. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3: 329-37.
19. Lemoine M, Ingiliz P. Liver injury in HIV monoinfected patients: should we turn a blind eye to it? Clin Res Hepatol Gastroenterol 2012; 36: 441-7.
20. Rivero-Juarez A, Camacho A, Merchante N et al. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One 2013; 8: e68953.
21. Kaslow RA, Ostrow DG, Detels R et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126: 310-8.
22. Dudley J, Jin S, Hoover D et al. The Multicenter AIDS Cohort Study: retention aft er 9 1/2 years. Am J Epidemiol 1995; 142: 323-30.
23. Lee SS, Park SH, Kim HJ et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52: 579-85.
24. Park SH, Kim PN, Kim KW et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.
25. Witt MD, Seaberg EC, Darilay A et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57: 77-84.
26. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
27. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
28. Price JC, Seaberg EC, Badri S et al. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis 2012; 205: 1005-13.
29. DeFilippis AP, Blaha MJ, Martin SS et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 2013; 227: 429-36.
30. Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Th ird National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.
31. Li Vecchi V, Soresi M, Giannitrapani L et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis 2012; 16: e397-402.
32. Ryan P, Blanco F, Garcia-Gasco P et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009; 10: 53-9.
33. Pickhardt PJ, Park SH, Hahn L et al. Specificity of unenhanced CT for noninvasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol 2012; 22: 1075-82.
34. Monto A, Dove LM, Bostrom A et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42: 310-6.
35. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44: 1026-32.
36. Castera L, Loko MA, Le Bail B et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther 2007; 26: 1489-98.
37. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-23.
38. Sookoian S, Pirola CJ. PNPLA3, the history of an orphan gene of the potate tuber PROTEIN family that found an organ: the liver. Hepatology 2014 (e-pub ahead of print).
39. Graff M, North KE, Franceschini N et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond) 2013; 37: 432-8.
40. Poynard T, Ratziu V, McHutchison J et al. effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
41. Felmlee DJ, Hafirassou ML, Lefevre M et al. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013; 5: 1292-324.
42. Lonardo A, Loria P, AdinolfiLE et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13: 73-80.
43. Stankov MV, Panayotova-Dimitrova D, Leverkus M et al. Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. AIDS 2012; 26: 1995-2006.
44. McGovern BH, Ditelberg JS, Taylor LE et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-72.
45. Macias J, Berenguer J, Japon MA et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56: 1261-70.